Cartesian Therapeutics (RNAC) Common Equity: 2015-2025
Historic Common Equity for Cartesian Therapeutics (RNAC) over the last 10 years, with Sep 2025 value amounting to -$35.8 million.
- Cartesian Therapeutics' Common Equity fell 4866.49% to -$35.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$35.8 million, marking a year-over-year decrease of 4866.49%. This contributed to the annual value of -$6.8 million for FY2024, which is 98.45% up from last year.
- Cartesian Therapeutics' Common Equity amounted to -$35.8 million in Q3 2025, which was down 1,318.44% from -$2.5 million recorded in Q2 2025.
- In the past 5 years, Cartesian Therapeutics' Common Equity registered a high of $93.8 million during Q4 2022, and its lowest value of -$440.2 million during Q4 2023.
- Its 3-year average for Common Equity is -$47.7 million, with a median of -$6.8 million in 2024.
- As far as peak fluctuations go, Cartesian Therapeutics' Common Equity surged by 2,222.36% in 2022, and later slumped by 4,866.49% in 2025.
- Over the past 5 years, Cartesian Therapeutics' Common Equity (Quarterly) stood at $22.5 million in 2021, then soared by 316.62% to $93.8 million in 2022, then slumped by 569.14% to -$440.2 million in 2023, then soared by 98.45% to -$6.8 million in 2024, then crashed by 4,866.49% to -$35.8 million in 2025.
- Its Common Equity stands at -$35.8 million for Q3 2025, versus -$2.5 million for Q2 2025 and -$21.8 million for Q1 2025.